COST-EFFECTIVENESS OF LENALIDOMIDE/DEXAMETHASONE IN MULTIPLE MYELOMA PATIENTS WITH A PRIOR THALIMODMIDE THERAPY

被引：0
|
作者：
Schey, S. [1 ]
Stern, S. [2 ]
Dhanasiri, S. [3 ]
Brown, R. [2 ]
机构：
[1] Kings Coll Hosp London, London, England
[2] United BioSource Corp, Bethesda, MD USA
[3] Celgene Ltd, Uxbridge, Middx, England
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1087
引用
收藏
页码：443 / 443
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of lenalidomide
    Antonio Olry de Labry Lima
    Antonio Matas Hoces
    Vicente Gimeno Ballester
    Esmeralda Ríos Sánchez
    Emilio Jesús Alegre del Rey
    Bone Marrow Transplantation, 2020, 55 : 853 - 854
  • [32] Cost-effectiveness of bortezomib in multiple myeloma
    Cecchi, Michele
    Caccese, Erminia
    Messori, Andrea
    Orsi, Cecilia
    Tendi, Enrico
    PHARMACY WORLD & SCIENCE, 2007, 29 (05): : 485 - 486
  • [33] Cost-Effectiveness of Daratumumab Plus Bortezomib and Dexamethasone Versus Bortezomib Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: An Analysis of the Castor Trial
    Maiese, Eric M.
    Graham, Christopher N.
    Hawe, Emma
    Le Moine, Jean-Gabriel
    Abraham, Ivo
    Senbetta, Mekre
    BLOOD, 2017, 130
  • [34] Cost-effectiveness of lenalidomide
    de Labry Lima, Antonio Olry
    Matas Hoces, Antonio
    Gimeno Ballester, Vicente
    Rios Sanchez, Esmeralda
    Alegre del Rey, Emilio Jesus
    BONE MARROW TRANSPLANTATION, 2020, 55 (05) : 853 - 854
  • [35] TWO COST-EFFECTIVENESS ANALYSES OF THE USE OF CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE VERSUS LENALIDOMIDE PLUS DEXAMETHASONE AND CARFILZOMIB PLUS DEXAMETHASONE VERSUS BORTEZOMIB PLUS DEXAMETHASONE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA IN COLOMBIA
    van Beurden-Tan, C.
    Forero, J.
    Coggia, A.
    Bustos Marquez, M. C.
    VALUE IN HEALTH, 2019, 22 : S480 - S480
  • [36] Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data
    Campioni, M.
    Agirrezabal, I.
    Hajek, R.
    Minarik, J.
    Pour, L.
    Spicka, I.
    Gonzalez-McQuire, S.
    Jandova, P.
    Maisnar, V.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2020, 21 (02): : 219 - 233
  • [37] Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data
    M. Campioni
    I. Agirrezabal
    R. Hajek
    J. Minarik
    L. Pour
    I. Spicka
    S. Gonzalez-McQuire
    P. Jandova
    V. Maisnar
    The European Journal of Health Economics, 2020, 21 : 219 - 233
  • [38] Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better
    Mohamad Mohty
    Florent Malard
    Ali Bazarbachi
    Clinical Hematology International, 2020, 2 (2) : 92 - 93
  • [39] Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma
    Usmani, S. Z.
    Cavenagh, J. D.
    Belch, A. R.
    Hulin, C.
    Basu, S.
    White, D.
    Nooka, A.
    Ervin-Haynes, A.
    Yiu, W.
    Nagarwala, Y.
    Berger, A.
    Pelligra, C. G.
    Guo, S.
    Binder, G.
    Gibson, C. J.
    Facon, T.
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (03) : 243 - 258
  • [40] Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States
    Jakubowiak, Andrzej J.
    Houisse, Ivan
    Majer, Istvan
    Benedict, Agnes
    Campioni, Marco
    Panjabi, Sumeet
    Ailawadhi, Sikander
    EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (12) : 1107 - 1119
12345